Freestone Grove Partners LP Makes New Investment in Agilent Technologies, Inc. $A

Freestone Grove Partners LP purchased a new stake in Agilent Technologies, Inc. (NYSE:A) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 685,699 shares of the medical research company’s stock, valued at approximately $91,081,000. Freestone Grove Partners LP owned 0.24% of Agilent Technologies at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in A. Core Wealth Advisors LLC bought a new position in Agilent Technologies in the 4th quarter worth approximately $26,000. SHP Wealth Management bought a new stake in Agilent Technologies during the 4th quarter valued at $26,000. Navalign LLC acquired a new position in Agilent Technologies during the 4th quarter worth $27,000. Cedar Mountain Advisors LLC acquired a new position in Agilent Technologies during the 1st quarter worth $27,000. Finally, MV Capital Management Inc. bought a new position in shares of Agilent Technologies in the fourth quarter worth $28,000.

Agilent Technologies Stock Up 0.3%

Shares of A stock opened at $155.16 on Thursday. Agilent Technologies, Inc. has a 1 year low of $108.35 and a 1 year high of $160.51. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.62 and a current ratio of 2.10. The business’s fifty day moving average is $139.16 and its 200-day moving average is $126.65. The stock has a market cap of $43.82 billion, a PE ratio of 31.16, a price-to-earnings-growth ratio of 2.73 and a beta of 1.25.

Agilent Technologies (NYSE:A) last announced its quarterly earnings data on Wednesday, August 26th. The medical research company reported $1.62 earnings per share for the quarter, beating the consensus estimate of $1.49 by $0.13. Agilent Technologies had a return on equity of 24.33% and a net margin of 19.55%.The business had revenue of $1.88 billion during the quarter, compared to analyst estimates of $1.84 billion. During the same quarter in the prior year, the firm posted $1.37 earnings per share. The company’s revenue was up 8.1% on a year-over-year basis. Agilent Technologies has set its Q4 2026 guidance at 1.710-1.740 EPS and its FY 2026 guidance at 6.180-6.210 EPS. Equities analysts expect that Agilent Technologies, Inc. will post 6.05 earnings per share for the current fiscal year.

Key Agilent Technologies News

Here are the key news stories impacting Agilent Technologies this week:

• Positive Sentiment: Agilent reported fiscal Q3 revenue of $1.88 billion, up 8.1% year over year and ahead of the roughly $1.84 billion consensus estimate. Adjusted EPS of $1.62 exceeded estimates near $1.48-$1.49 and rose from $1.37 a year earlier. Agilent Technologies Q3 Earnings and Revenues Top Estimates
• Positive Sentiment: Profitability and cash generation strengthened. Operating profit increased 23.3% to $444 million, operating cash flow rose 43.4% to $519 million, and the company ended the quarter with $1.8 billion in cash. GAAP net income reached $362 million, or $1.28 per diluted share, versus $336 million, or $1.18, a year earlier. Agilent Reports Third-Quarter Fiscal Year 2026 Financial Results
• Positive Sentiment: Agilent raised fiscal 2026 adjusted EPS guidance to $6.18-$6.21, above the approximately $6.06 consensus, and projected revenue of about $7.5 billion versus expectations near $7.4 billion. Management cited improving laboratory-tools demand. Fourth-quarter guidance was broadly in line with analyst estimates. Agilent Raises Annual Profit Forecast
• Neutral Sentiment: Institutional investor positioning was mixed: 594 investors increased holdings in the latest quarter, while 550 reduced positions. Recent analyst targets have a median of $155, suggesting limited near-term upside relative to the recent trading level.
• Negative Sentiment: Despite the earnings beat, Agilent trades at a relatively demanding valuation, with a P/E ratio above 31, and the stock is close to its 12-month high. This could make the shares more sensitive to any slowdown in laboratory-equipment demand or future guidance disappointments.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Wolfe Research reissued a “hold” rating on shares of Agilent Technologies in a report on Tuesday, June 2nd. Barclays upped their price objective on shares of Agilent Technologies from $145.00 to $150.00 and gave the stock an “overweight” rating in a report on Wednesday, June 24th. Robert W. Baird increased their target price on shares of Agilent Technologies from $155.00 to $156.00 and gave the company an “outperform” rating in a research report on Tuesday, May 26th. Weiss Ratings upgraded shares of Agilent Technologies from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, June 2nd. Finally, TD Cowen boosted their price target on shares of Agilent Technologies from $147.00 to $155.00 and gave the stock a “buy” rating in a research report on Thursday, May 28th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $160.24.

Agilent Technologies Company Profile

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.